Restoring Veeva Systems to Watch List
Jun 2, 2024
With Q1 sales growth of almost 24%, Veeva has returned to the Green Screens and will return to the Watch List as well. This specialized pharmaceutical SaaS provider continues to have an outstanding economic moat, and growth is re-accelerating after a few slow years. My fair value estimate is $186. The stock trades a touch below that at present, making this one a close watch for Buy List addition in the near future.
Follow @GreenDotStocks
Information contained on this website represents only the opinions of the author and should not be used as the sole basis for investing decisions. By using this site, you agree to all statements in the Site Policy.
Watch List
| APPF | 0.31% |
| S | 7.90% |
| NTNX | 29.15% |
| CRWD | 94.58% |
| SEMR | 10.97% |
| SNOW | 23.53% |
| SE | 72.46% |
vs. Fair Value Estimates
Buy List
| TSM | -26.30% |
| GOOG | -44.13% |
| NYAX | -44.21% |
| MSFT | -25.64% |
| ASR | -28.40% |
| HRMY | -49.18% |
| YOU | -51.94% |
| ADBE | -31.43% |
vs. Fair Value Estimates
Hold List
| ZETA | -15.39% |
| ODD | -23.48% |
| FLYW | -8.26% |
| CELH | 1.94% |
| TOST | 25.67% |
| CPNG | 5.62% |
| HIMS | 76.00% |
| PAYC | -23.36% |
| MNDY | 30.15% |
| GLBE | -2.02% |
| ZS | 25.67% |
| V | -3.45% |
| ADSK | 6.74% |
| NOW | 13.33% |
| ABNB | -17.94% |
| MELI | -22.12% |
| FTNT | 7.86% |
| TEAM | 25.43% |
vs. Fair Value Estimates